SSTR-positive neuroendocrine tumors: peptide receptor radionuclide therapy

被引：0
|
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S66 / S69
页数：4
相关论文
共 50 条
  • [21] Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201
    Nicolas, G.
    Baum, R.
    Herrmann, K.
    Lassmann, M.
    Hicks, R.
    Haug, A. R.
    Oberwittler, H.
    Bouterfa, H.
    Wang, T.
    Wild, D.
    NEUROENDOCRINOLOGY, 2017, 105 : 250 - 250
  • [22] Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
    Ladwa, Rahul
    Wen Hong, Hooi
    Wyld, David
    Pattison, David A.
    Burge, Matthew
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (03) : 186 - 187
  • [23] Addendum to the Editorial "Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors"
    Delbeke, Dominique
    Graham, Michael M.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (07) : 1170 - 1170
  • [24] The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors
    Bodei, Lisa
    Cwikla, Jaroslaw B.
    Kidd, Mark
    Modlin, Irvin M.
    JOURNAL OF THORACIC DISEASE, 2017, 9 : S1511 - S1523
  • [25] Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors
    El Ferkh, R.
    Hadoux, J.
    Lamartina, L.
    Kamoun, T.
    Cysique-Foinlan, L.
    Jepiral, G.
    Ducreux, M. P.
    Baudin, E.
    Marzac, C.
    Micol, J. Baptiste
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S954 - S955
  • [26] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: how important is internal dosimetry?
    Trauernicht, Christoph
    du Toit, Pieter
    SOUTH AFRICAN JOURNAL OF SURGERY, 2019, 57 (01) : 57 - 57
  • [27] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
    Duan, H.
    Girod, B.
    Ninatti, G.
    Ferri, V
    Kunz, P.
    Fisher, G.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Lagaru, A.
    Aparici, Mari C.
    NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
  • [28] Peptide receptor radionuclide therapy and theranostics beyond neuroendocrine tumors and into the next decade
    Satz, S.
    Baum, R. P.
    Sathekge, M. M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [29] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
  • [30] Treatment guidelines for pancreatic neuroendocrine tumors (except peptide receptor radionuclide therapy)
    Duval, M.
    Vezzosi, D.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2020, 24 (4-5): : 152 - 156
12345